SlideShare ist ein Scribd-Unternehmen logo
1 von 6
Downloaden Sie, um offline zu lesen
REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
UBM ADVANSTAR
PUBLICATIONS
R E G I S T E R BY M A R C H 2 7, 2 0 1 5 A N D S AV E $ 3 0 0 !
Media
Partners:
MAY 19-20, 2015 • DOUBLETREE BY HILTON • SILVER SPRING, MD
Navigate the Rapidly Changing Requirements for
Minimizing the Misuse Potential of Highly Abused Drugs
Link ADFs that Effectively Decrease Abuse and
Misuse Potential to Optimal Label Claims:
	 Assess whether the FDA Final Guidance has
adequately assisted sponsors with opioid drug
product formulation development
	 Examine current ADF collaborations between
industry and congress
	 Utilize formulation technologies and
analytical, clinical and statistical evaluation
methods to achieve FDA approval
	 Address the uncertainty in generic drug
development — Will FDA approval be tied to ADF?
	 Sharpen regulatory liaison best practices for
managing post-submission questions and
responses from the FDA
	 Rapidly respond to FDA questions with transparent
and direct answers to facilitate a cleaner review
	 Identify appropriate ways to communicate abuse
deterrent claims in product labels
	 Consider options for manipulating drug products
and extended-release formulations to counteract
over-medicating
Featured Thought Leaders:
CHAIRPERSON
Penny Levin,
Director, Global Regulatory
Intelligence & Policy
Teva
Kevin Sills,
Vice President,
R&D,
Atlantic
Pharmaceuticals
Kevin Healy, Ph.D.,
Director,
Regulatory Affairs,
Mallinckrodt
Pharmaceuticals
Tim Hermes,
Vice President,
Government Affairs and
Alliance Development,
Collegium
Pharmaceuticals, Inc.
Jeffrey M. Dayno, M.D.,
Chief Medical Officer,
Egalet Corporation
Dan Cohen,
Leader, U.S. Abuse
Deterrent Coalition;
Head of North American
Government Relations,
Grünenthal USA, Inc.
Life Sciences
Association Partner:
REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
A Great Place to Meet Your Market!
Take advantage of the best opportunity to meet potential clients face-to-face. Build relationships while demonstrating thought
leadership and sharing expertise. For more information on how to position your company as a sponsor or exhibitor, contact
Lauren Moras at 339-298-2172 or email lauren.moras@cbinet.com.
Who Should Attend
You will benefit from attending this event if you are a senior executive, senior director, director
or manager from the pharmaceutical or biotech industries with responsibilities or involvement in the
following areas:
Regulatory Affairs • Regulatory Intelligence • Risk Management/REMS
Pharmacovigilance/Drug Safety • Clinical Development • Epidemiology • Pharmacoepidemiology
Formulary Development/CMC • Health/Government Policy • Medical Affairs
This conference will also benefit consultants, CROs, central labs, drug safety service providers and
companies providing services to the above audience.
CBI’s Abuse Deterrent Formulations Summit
focuses on critical abuse and misuse reduction
strategies, including best practices for meeting
regulatory requirements, implementing risk
mitigation, developing protocols to evaluate
liability and achieving an ADF label from
the FDA.
As the FDA continues to focus on reducing the
abuse potential of opioids, it is more important
than ever for bio/pharma manufacturers to
ensure that new and existing products are
meeting regulatory mandates and minimizing
misuse potential and abuse liability.
How will your organization respond?
“While prescription opioids are an important component of pain management,
abuse and misuse of these products have resulted in too many injuries and
deaths across the United States. An important step towards the goal of creating
safer opioids is the development of products that are specifically formulated to
deter abuse.”
- 	Douglas Throckmorton, M.D., Deputy Director, Regulatory Programs,
	 Center for Drug Evaluation and Research, FDA *Source: FDA.gov, January, 2013
Conference Sponsors:
DAY ONE
Tuesday, May 19, 2015
7:45	 Conference Registration and Breakfast
8:45	 Chairperson’s Opening Remarks
PennyLevin,Director,GlobalRegulatoryIntelligence&Policy,Teva
	 Unravel Evolving ADF
Regulatory Requirements to
Minimize Human Abuse Liability
9:00	 Policy Address
Setting the Scene — The Future of
	 Abuse Deterrent Formulations for
	 Minimizing American Drug Abuse
•	 Hear an overview of the prescription drug abuse
	 epidemic, including the FDA’s Abuse Deterrent
	 Opioids — Evaluation and Labeling final guidance
* does the final guidance adequately assist
	 sponsors with opioid drug product
	 formulation development and set forth an
	 understanding of what is expected?
* how are the studies evaluated? What have
	 been the subsequent labeling claims?
* why generic draft guidance is so important?
• 	 Discuss how industry can reach the goal of
	 decreasing abuse and misuse in the community
• 	 Evaluate ADFs as a method to reduce abuse while
	 ensuring access to medication for
	 patients with legitimate medical needs
* discuss the extent to which abuse
	 reduction can be measured
* consider pros and cons of ADFs
• 	 Identify policy recommendations to transition
	 the market to abuse-deterrent formulations
	 for both branded and generic products
* assess how policy recommendations
	 impact market access
StaceyL.Worthy,Esq.,AssociateAttorney,DCBA Law & Policy
KyleSimon,Director,PolicyandAdvocacy,Center for Lawful
Access and Abuse Deterrence (CLAAD)
10:00 	 State of the Union — What’s Going on in
Congress and the States?
Addressing prescription drug abuse is an issue high
on legislative agendas in Washington, D.C. and in
state legislatures across the country. Topics to be
addressed in this session include:
•	 What is going to happen in Congress?
•	 Who are the key policymakers to watch?
•	 What are they saying?
•	 What states are leading the way to incentivize
adoption of abuse deterrence formulations?
•	 What is the industry doing to advance the cause?
RobertJ.Falb,Director,GovernmentandPublicAffairsDepartment,
Teva
10:30	 Networking and Refreshment Break
11:00	 Understand Pre-Marketing Regulatory
Expectations and Clinical Processes to
Ensure Compliance with FDA
Final Guidance
• 	 Implement early planning and
pre-IND considerations
• 	 Discuss ADF Category 1 Studies —
	 Formulation analyses and in vitro testing
• 	 Examine ADF Category 2 (PK) and Category 3
	 (HAP) Studies — Design and FDA protocol review
• 	 Consider overall clinical program requirements —
Collecting and reporting pertinent information
• 	 Prepare for the pre-NDA meeting and organize
	 the NDA submission
	 Discuss labeling considerations and the
NDA review
KevinHealy,Ph.D.,SeniorDirector,RegulatoryAffairs,
Mallinckrodt Pharmaceuticals
11:45	 Examine the Development of Opioid
and Non-Opioid Abuse Deterrent
Formulations to Reduce Liability and
Meet Regulatory Expectations
•	 Consider the deterrence science for rapid
evolution of ADFs
•	 Utilize formulation technologies and analytical,
clinical and statistical evaluation methods to
achieve FDA approval
•	 Examine general considerations for study design
•	 Explore the most common routes of abuse
for the particular drug in development
•	 Evaluate the concept of abuse potential
•	 Implement approaches to assess the abuse
potential of a drug product
•	 Perform Human Abuse Potential (HAP) studies for
drugs with addictive potential
•	 Characterize the pharmacokinetic (PK)/
pharmacodynamic (PD) properties of a
substance and a product
•	 Discuss which opioid safety recommendations will
be expanded into non-opioid drug development
•	 Discover pitfalls and successes within the opioid
market and how non-opioid products can learn
from the failures and achievements
TerriL.Morton,Ph.D.,SeniorPrincipalClinicalPharmacologist,
Mallinckrodt Pharmaceuticals
12:30	 Networking Luncheon
REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
1:45	 ROUNDTABLE
Consider FDA Future Action for
Generic Opioid Analgesic Treatment —
Will Approval be Tied to ADF?
During this interactive roundtable, attendees
break into discussion groups to share insights
on considerations for generic drug development
with ADF. Participants then reconvene for shared
learning to highlight key insights and discussion
points of each individual group. Topics to be
addressed include:
• 	 Examine FDA’s focus on ADF generic opioid
	 development and what any changes in
	 regulation could mean for development
• 	 Identify necessary considerations for generic
	 product ADFs
* 	will non-abuse deterrent opioid generics
	 be kept off the market?
* 	are there strategies for creating similar
	 abuse deterrent formulations that may be
	 able to match the branded product?
* 	does a generic clinical study, claim and
	 tier need to match that exactly of the
	 branded product?
* 	do the same suggestions that are laid out in
	 the final guidance apply to generic products?
• 	 Gauge the potential for the future of generic
	 drug development
KevinSills,VicePresident,R&D,Atlantic Pharmaceuticals
2:45	 Networking and Refreshment Break
	 Develop Best Practices to
Achieve FDA Approval and
Ensure Market Success
3:15	 Regulatory Liaison Best Practices for
Managing Post-Submission Questions and
Answers to and from the FDA
•	 Create a rapid response team, including point
persons for dossier review prior to submission
*	go through dossier with fine tooth comb to
identify any potential questions from the FDA
and multiple answers ahead of time
•	 Ensure that appropriate R&D, regulatory,
commercial, etc., team members are accessible
when needed throughout the lifecycle of the
submission; filing, acceptance, review
•	 Respond to FDA questions, rapidly, with
transparent and direct answers to facilitate a much
cleaner review
PennyLevin,Director,GlobalRegulatoryIntelligence&Policy,Teva
4:00 	 The Holy Grail of Abuse Deterrence
•	 Examine the full extent of abuse deterrence —
Can the current focus of ADF technologies on
external manipulation of oral doses also protect
the motivated abuser from accidental
or intentional overdose?
•	 Discuss the financial implications of developing
abuse deterrence technologies
RonGuido,CEO,ExxPharma Therapeutics, LLC
4:45	 Close of Day One
Networking, Wine and Cheese Reception
immediately following the final session on day one
DAY TWO
Wednesday, May 20, 2015
8:00 	 Continental Breakfast
8:30 	 Chairperson’s Review of Day One
PennyLevin,Director,GlobalRegulatoryIntelligence&Policy,Teva
8:45	 INTERACTIVE LIVE POLLING
Educate Medical Professionals,
Patients and the Public on the Safe
Use of Opioids and Stimulants
How it works…Make sure to have your mobile
device handy. Text answers to questions and
see your results in real time.
•	 Address how public policy collaborations with the
government and with regulators need to evolve to
provide the necessary formulated deterrence
•	 Identify and define abuse deterrent
developers’ role in educating the public for
safe conduct and use of opioid and stimulant
•	 Establish goals and aims of AD Coalition
public policy initiatives
DanCohen,Leader,U.S. Abuse Deterrent Coalition;Headof
NorthAmericanGovernmentRelations,Grünenthal USA, Inc.
	 Develop Strategies for Label
Claims and Formulations in
New and Existing Drugs
9:30	 Generate and Translate Data from
ADF Development into Label Claims
and Communicate the Data to
Various Stakeholders
• 	 Review the FDA final guidance on Abuse Deterrent
Opioid Development to understand the following:
*	different categories of abuse deterrent studies
* 	different tiers of claims for product labels
* 	how the different categories of data
	 do/do not translate to label claims
REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
• 	 Appreciate the current approach and challenges
	 in abuse deterrent opioid development in the
	 context of “incremental improvement”
• 	 Identify appropriate ways for sponsors to
	 communicate abuse deterrent claims in
	 product labels
• 	 Anticipate challenges in the post-approval
	 phase of an abuse deterrent opioid:
* 	Category 4 abuse deterrent studies —
	 A post-approval requirement
* 	other ‘real world’ exposure of a product and its
potential impact on its abuse deterrent profile
JeffreyM.Dayno,M.D.,ChiefMedicalOfficer,Egalet Corporation
10:15	 Networking and Refreshment Break
10:45	 Leverage Pharmacokinetic Studies to
Support Tier 2 Labeling Claims for
Abuse Deterrent Opioids
•	 Provide an overview of the FDA’s Abuse-
Deterrent Opioids Guidance with respect to
pharmacokinetic studies and Tier 2 labeling
•	 Discuss the type of pharmacokinetic studies
required to support Tier 2 claims
•	 Consider different formulation manipulations
and administration routes and how they can
support Tier 2 labeling
•	 Present strategies of using pharmacokinetic
studies to help support Tier 1 and Tier 3
labeling claims
JohnOldenhof,MSc,Ph.D.,SeniorDirectorScientificAffairs,
INC Research
11:30 	 Utilize Formulation Technologies to
Impart Abuse Deterrent Properties
and ADF Testing
•	 Discuss formulation technologies used in:
*	Aversion Oxycodone (formerly Oxecta)
*	Remoxy
*	Embeda
*	Bunavail
•	 Examine the different types of ADF testing
and the need for standards
•	 Consider the potential for AD labeling
•	 Deliberate what the future may hold for
AD properties and testing
JulieS.Ross,Ph.D.,Director,FormulationDevelopment,
BioDelivery Sciences International
12:15 	 Networking Luncheon
1:30 	 The Search for New Pain Therapeutics
with Low Inherent Abuse Potential —
A Case for Prodrugs
•	 Examine the history of prodrugs with abuse
deterrent properties
•	 Adapt biochemistry within clinical development
to control abuser preference and enjoyment
*	prodrug development and combination
of formulations
•	 Consider options for manipulating drug
products and extended-release formulations
to decrease the ability for oral formulation to
counteract overmedicating
•	 Examine potential for use within the opioid
analgesic drug class and the potential to
evolve similar formulations for other
addictive therapeutics
SvenGuenther,Ph.D.,EVP,ResearchandDevelopment,
KemPharm, Inc.
2:15	 ROUNDTABLE
True Objectives of Abuse Deterrence —
Addiction vs. Abuse?
While 15% of opioid abuse is through insufflation
(snorting), or injection, the majority of abuse is that
of quantity of opioid ingested. While the focus has
been on decreasing the street value of opioids,
the larger issue remains taking more opioid than
prescribed. During this interactive roundtable,
attendees break into discussion groups to share
insights on objectives for minimizing abuse.
Participants then reconvene for shared learning to
highlight key insights and discussion points of
each individual group. Questions to be
addressed include:
•	 Should we be focusing on how to make
effective pain medications that are less
addictive, with lower amounts of euphoria or
withdrawal symptoms?
•	 What can we learn from studying patient
preference and the effect of different opioids
on different patients types?
•	 Can we avoid situations where acute patients
become chronic patients with managing
medication therapy management?
•	 Physical manipulation of opioids only addresses
part of the problem; are likability and abuse
potential truly the same thing?
TimHermes,VicePresident,GovernmentAffairsandAlliance
Development,Collegium Pharmaceuticals, Inc.
3:00 	 Close of Conference
REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
SCAN HERE
CBI
70 Blanchard Road
Burlington, MA 01803
4WAYS TO REGISTER NOW!
PHONE
800-817-8601
339-298-2100 outside the U.S.
E-MAIL
cbireg@cbinet.com
WEBSITE
www.cbinet.com/adf
LIVE CHAT
www.cbinet.com/adf
Life Sciences
Abuse Deterrent Formulations Summit							 PC15098
VENUE:
DoubleTree by Hilton Silver Spring
8727 Colesville Road
Silver Spring, Maryland 20910
Phone Reservations: (800) 222-8733
Hotel Direct Line: (301) 589-5200
ACCOMMODATIONS:
To receive CBI’s special discounted hotel rate online or by phone, please go to:
• Online: www.cbinet.com/adf
• Phone reservations: (800) 222-8733 and mention CBI’s Abuse Deterrent 		
Formulations.
Book Now! The DoubleTree by Hilton Silver Spring is accepting reservations on a
space and rate availability basis. Rooms are limited, so please book early. All travel
arrangements subject to availability.
PLEASE NOTE: All hotel reservations for this conference should be booked directly
with the hotel. CBI does not use Housing Bureaus and none are authorized to call
on our behalf.
REGISTRATION FEE:
	 ADVANTAGE PRICING	Standard
Conference 	 $1899	 $2199
Register by March 27, 2015 and SAVE $300. Fee includes continental breakfast, lunch,
wine and cheese reception, refreshments and conference documentation. Please make checks
(in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.)
PLEASE NOTE: All advertised discounts are taken from the full, Standard Rate.
TEAM DISCOUNT:
For every three paying registrations from your company, you will receive a fourth complimentary*
registration to the conference (must register four at same time to qualify). To receive the team discount
you must register with our customer service department by calling 339-298-2100.
* Advantage pricing rates do apply when applicable. Offer may not be combined with any other
special pricing promotions. Offer may be used at CBI co-located events.
SATISFACTION GUARANTEED:
CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference,
a credit will be awarded towards a comparable CBI conference of your choice. Please contact 800-817-
8601 for further information. Advanced preparation for CBI conferences is not required.
SUBSTITUTION AND CANCELLATION:
Your registration may be transferred to a member of your organization up to 24 hours in advance of the
conference. Cancellations received in writing on or before 14 days prior to the start date of the event
will be refunded, less a $399 administrative charge. No refunds will be made after this date; however,
the registration fee less the $399 administrative charge can be credited to another CBI conference if
you register within 30 days from the date of this conference to an alternative CBI conference scheduled
within the next six months. In case of conference cancellation, CBI’s liability is limited to refund of the
conference registration fee only. CBI reserves the right to alter this program without prior notice. Please
Note: Speakers and agenda are subject to change. In the event of a speaker cancellation, every effort
to find a suitable replacement will be made without notice. The opinions of the conference faculty do
not necessarily reflect those of the companies they represent or CBI.
REGISTE R AT WWW.CBINET.COM/ADF • 800-817-8601
R E G I S T E R BY M A R C H 2 7, 2 0 1 5 A N D S AV E $ 3 0 0 !
MAY 19-20, 2015 • DOUBLETREE BY HILTON • SILVER SPRING, MD
Navigate the Rapidly Changing Requirements for
Minimizing the Misuse Potential of Highly Abused Drugs
ANY QUESTIONS OR TO REGISTER
CALL Christian Alongi 339-298-2131
or FAX TO MY ATTENTION 781-939-2694
email: christian.alongi@cbinet.com

Weitere ähnliche Inhalte

Was ist angesagt?

Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...Peter Dellva
 
Health Canada Drug Names 2016
Health Canada Drug Names 2016Health Canada Drug Names 2016
Health Canada Drug Names 2016Brand Acumen
 
Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Ajaz Hussain
 
Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers TGA Australia
 
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018"."Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".Rosmirella Cano Rojas
 
Reducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentReducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentAjaz Hussain
 
WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?
WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?
WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?ambitbiomedix12
 
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
RyMat Inc.: A Look At Generic vs. Brand PharmaceuticalsRyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
RyMat Inc.: A Look At Generic vs. Brand PharmaceuticalsStuart Silverman
 
Global Promotional Review
Global Promotional Review Global Promotional Review
Global Promotional Review Alan Bergstrom
 
Brand drug vs generic drug
Brand drug vs generic drugBrand drug vs generic drug
Brand drug vs generic drugShubham Paul
 
Presentation: Updates from the Therapeutic Goods Administration - For medicin...
Presentation: Updates from the Therapeutic Goods Administration - For medicin...Presentation: Updates from the Therapeutic Goods Administration - For medicin...
Presentation: Updates from the Therapeutic Goods Administration - For medicin...TGA Australia
 
Generic vs branded medicine
Generic vs branded medicineGeneric vs branded medicine
Generic vs branded medicineTushar Morankar
 
Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12MichaelMcNamara
 
UNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESSUNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESSKabin Maleku
 
Sustainable Procurement Index for Health (SPIH) Clinic
Sustainable Procurement Index for Health (SPIH) ClinicSustainable Procurement Index for Health (SPIH) Clinic
Sustainable Procurement Index for Health (SPIH) ClinicUN SPHS
 

Was ist angesagt? (20)

Harmonization and Opportunites (Nov 2015)
Harmonization and Opportunites (Nov 2015)Harmonization and Opportunites (Nov 2015)
Harmonization and Opportunites (Nov 2015)
 
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...
 
Health Canada Drug Names 2016
Health Canada Drug Names 2016Health Canada Drug Names 2016
Health Canada Drug Names 2016
 
Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015
 
New Broker's Sales Presentation
New Broker's Sales PresentationNew Broker's Sales Presentation
New Broker's Sales Presentation
 
Generics And Innovators
Generics And InnovatorsGenerics And Innovators
Generics And Innovators
 
Brand vs Generic -A War?
Brand vs Generic -A War?Brand vs Generic -A War?
Brand vs Generic -A War?
 
Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers
 
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018"."Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".
 
Reducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentReducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar development
 
WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?
WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?
WHAT IS THE DIFFERENCE BETWEEN PCD, GENERIC, AND ETHICAL PHARMA SECTORS?
 
Resume
ResumeResume
Resume
 
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
RyMat Inc.: A Look At Generic vs. Brand PharmaceuticalsRyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
 
Global Promotional Review
Global Promotional Review Global Promotional Review
Global Promotional Review
 
Brand drug vs generic drug
Brand drug vs generic drugBrand drug vs generic drug
Brand drug vs generic drug
 
Presentation: Updates from the Therapeutic Goods Administration - For medicin...
Presentation: Updates from the Therapeutic Goods Administration - For medicin...Presentation: Updates from the Therapeutic Goods Administration - For medicin...
Presentation: Updates from the Therapeutic Goods Administration - For medicin...
 
Generic vs branded medicine
Generic vs branded medicineGeneric vs branded medicine
Generic vs branded medicine
 
Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12
 
UNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESSUNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESS
 
Sustainable Procurement Index for Health (SPIH) Clinic
Sustainable Procurement Index for Health (SPIH) ClinicSustainable Procurement Index for Health (SPIH) Clinic
Sustainable Procurement Index for Health (SPIH) Clinic
 

Andere mochten auch

INOVI - Catalogue 2014
INOVI - Catalogue 2014INOVI - Catalogue 2014
INOVI - Catalogue 2014Lucian Toma
 
7 lucruri de realizat pana la 30 de ani
7 lucruri de realizat pana la 30 de ani7 lucruri de realizat pana la 30 de ani
7 lucruri de realizat pana la 30 de aniclaudeea123
 
iGlass Catalogue - 2015 - EN
iGlass Catalogue - 2015 - ENiGlass Catalogue - 2015 - EN
iGlass Catalogue - 2015 - ENLucian Toma
 
SECDEF Memo: Installation Access for Nonprofits
SECDEF Memo: Installation Access for NonprofitsSECDEF Memo: Installation Access for Nonprofits
SECDEF Memo: Installation Access for NonprofitsChristopher Ford
 

Andere mochten auch (20)

INOVI - Catalogue 2014
INOVI - Catalogue 2014INOVI - Catalogue 2014
INOVI - Catalogue 2014
 
Funding Opportunities for Premium Transit Corridors Presenation
Funding Opportunities for Premium Transit Corridors PresenationFunding Opportunities for Premium Transit Corridors Presenation
Funding Opportunities for Premium Transit Corridors Presenation
 
pc15147_brochure
pc15147_brochurepc15147_brochure
pc15147_brochure
 
LRTP Freight Projects, October 22, 2014
LRTP Freight Projects, October 22, 2014LRTP Freight Projects, October 22, 2014
LRTP Freight Projects, October 22, 2014
 
pc15136_brochure
pc15136_brochurepc15136_brochure
pc15136_brochure
 
7 lucruri de realizat pana la 30 de ani
7 lucruri de realizat pana la 30 de ani7 lucruri de realizat pana la 30 de ani
7 lucruri de realizat pana la 30 de ani
 
Mpo annual report 2013 final web
Mpo annual report 2013 final webMpo annual report 2013 final web
Mpo annual report 2013 final web
 
Promo resume
Promo resumePromo resume
Promo resume
 
pc15007_brochure
pc15007_brochurepc15007_brochure
pc15007_brochure
 
iGlass Catalogue - 2015 - EN
iGlass Catalogue - 2015 - ENiGlass Catalogue - 2015 - EN
iGlass Catalogue - 2015 - EN
 
fiel
fielfiel
fiel
 
Freight Roundtable at PortMiami, February 10, 2016
Freight Roundtable at PortMiami, February 10, 2016Freight Roundtable at PortMiami, February 10, 2016
Freight Roundtable at PortMiami, February 10, 2016
 
aspa 10th annual best practices conference
aspa 10th annual best practices conferenceaspa 10th annual best practices conference
aspa 10th annual best practices conference
 
MiMo Historic District Walkable Village Presentation
MiMo Historic District Walkable Village PresentationMiMo Historic District Walkable Village Presentation
MiMo Historic District Walkable Village Presentation
 
MDX 2015-2019 Work Program Overview presentation, October 22, 2014
MDX 2015-2019 Work Program Overview presentation, October 22, 2014MDX 2015-2019 Work Program Overview presentation, October 22, 2014
MDX 2015-2019 Work Program Overview presentation, October 22, 2014
 
Best Practices in BRT Presentation
Best Practices in BRT PresentationBest Practices in BRT Presentation
Best Practices in BRT Presentation
 
Miami-Dade MPO Transit Solutions Committee Meeting Presentation
Miami-Dade MPO Transit Solutions Committee Meeting PresentationMiami-Dade MPO Transit Solutions Committee Meeting Presentation
Miami-Dade MPO Transit Solutions Committee Meeting Presentation
 
Chinese Delegation Presentation - Chinese
Chinese Delegation Presentation - ChineseChinese Delegation Presentation - Chinese
Chinese Delegation Presentation - Chinese
 
SECDEF Memo: Installation Access for Nonprofits
SECDEF Memo: Installation Access for NonprofitsSECDEF Memo: Installation Access for Nonprofits
SECDEF Memo: Installation Access for Nonprofits
 
2040 RTP Rollout Event Presentation
2040 RTP Rollout Event Presentation2040 RTP Rollout Event Presentation
2040 RTP Rollout Event Presentation
 

Ähnlich wie pc15098_brochure

What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...Nathan White, CPC
 
How early is too early charles view 5jun2017
How early is too early charles view 5jun2017How early is too early charles view 5jun2017
How early is too early charles view 5jun2017Stephen Murdock
 
Get Your Development Program Started on the Right Foot
Get Your Development Program Started on the Right FootGet Your Development Program Started on the Right Foot
Get Your Development Program Started on the Right FootBrook White, PMP
 
Rx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthyRx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthyOPUNITE
 
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...ComplianceOnline
 
IND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAIND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAMANIKANDAN V
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRama Shukla
 
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2Ajaz Hussain
 
Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Bharathiar university
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
Research Use Only Products – the Dos and Don’ts - By Compliance Global Inc
Research Use Only Products – the Dos and Don’ts - By Compliance Global IncResearch Use Only Products – the Dos and Don’ts - By Compliance Global Inc
Research Use Only Products – the Dos and Don’ts - By Compliance Global IncCompliance Global Inc
 
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide AccessClinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide AccessE. Dennis Bashaw
 
FDA applications in a nutshell
FDA applications in a nutshellFDA applications in a nutshell
FDA applications in a nutshellGwenHb
 
Helping Pharmas Manage Compliance Risks for Speaker Programs
Helping Pharmas Manage Compliance Risks for Speaker ProgramsHelping Pharmas Manage Compliance Risks for Speaker Programs
Helping Pharmas Manage Compliance Risks for Speaker ProgramsCognizant
 
Industry and fda liaison
Industry and fda liaisonIndustry and fda liaison
Industry and fda liaisonPawanYadav285
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014Dinesh T
 

Ähnlich wie pc15098_brochure (20)

What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
 
How early is too early charles view 5jun2017
How early is too early charles view 5jun2017How early is too early charles view 5jun2017
How early is too early charles view 5jun2017
 
Get Your Development Program Started on the Right Foot
Get Your Development Program Started on the Right FootGet Your Development Program Started on the Right Foot
Get Your Development Program Started on the Right Foot
 
Rx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthyRx15 le wed_1115_1_meinhofer_2simon-worthy
Rx15 le wed_1115_1_meinhofer_2simon-worthy
 
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
Drug Master Files (DMFs) - Understanding and Meeting Your Global Regulatory a...
 
IND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDAIND, NDA, ANDA, SNDA
IND, NDA, ANDA, SNDA
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical Industry
 
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
 
Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
Research Use Only Products – the Dos and Don’ts - By Compliance Global Inc
Research Use Only Products – the Dos and Don’ts - By Compliance Global IncResearch Use Only Products – the Dos and Don’ts - By Compliance Global Inc
Research Use Only Products – the Dos and Don’ts - By Compliance Global Inc
 
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide AccessClinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
 
FDA applications in a nutshell
FDA applications in a nutshellFDA applications in a nutshell
FDA applications in a nutshell
 
Helping Pharmas Manage Compliance Risks for Speaker Programs
Helping Pharmas Manage Compliance Risks for Speaker ProgramsHelping Pharmas Manage Compliance Risks for Speaker Programs
Helping Pharmas Manage Compliance Risks for Speaker Programs
 
Industry and fda liaison
Industry and fda liaisonIndustry and fda liaison
Industry and fda liaison
 
pc14164_brochure-1
pc14164_brochure-1pc14164_brochure-1
pc14164_brochure-1
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
7th pharmacovigilance 2014
7th pharmacovigilance 20147th pharmacovigilance 2014
7th pharmacovigilance 2014
 
MS_Reg Sci One Page Flyer 2014-2015
MS_Reg Sci One Page Flyer 2014-2015MS_Reg Sci One Page Flyer 2014-2015
MS_Reg Sci One Page Flyer 2014-2015
 

pc15098_brochure

  • 1. REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601 UBM ADVANSTAR PUBLICATIONS R E G I S T E R BY M A R C H 2 7, 2 0 1 5 A N D S AV E $ 3 0 0 ! Media Partners: MAY 19-20, 2015 • DOUBLETREE BY HILTON • SILVER SPRING, MD Navigate the Rapidly Changing Requirements for Minimizing the Misuse Potential of Highly Abused Drugs Link ADFs that Effectively Decrease Abuse and Misuse Potential to Optimal Label Claims: Assess whether the FDA Final Guidance has adequately assisted sponsors with opioid drug product formulation development Examine current ADF collaborations between industry and congress Utilize formulation technologies and analytical, clinical and statistical evaluation methods to achieve FDA approval Address the uncertainty in generic drug development — Will FDA approval be tied to ADF? Sharpen regulatory liaison best practices for managing post-submission questions and responses from the FDA Rapidly respond to FDA questions with transparent and direct answers to facilitate a cleaner review Identify appropriate ways to communicate abuse deterrent claims in product labels Consider options for manipulating drug products and extended-release formulations to counteract over-medicating Featured Thought Leaders: CHAIRPERSON Penny Levin, Director, Global Regulatory Intelligence & Policy Teva Kevin Sills, Vice President, R&D, Atlantic Pharmaceuticals Kevin Healy, Ph.D., Director, Regulatory Affairs, Mallinckrodt Pharmaceuticals Tim Hermes, Vice President, Government Affairs and Alliance Development, Collegium Pharmaceuticals, Inc. Jeffrey M. Dayno, M.D., Chief Medical Officer, Egalet Corporation Dan Cohen, Leader, U.S. Abuse Deterrent Coalition; Head of North American Government Relations, Grünenthal USA, Inc. Life Sciences Association Partner:
  • 2. REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601 A Great Place to Meet Your Market! Take advantage of the best opportunity to meet potential clients face-to-face. Build relationships while demonstrating thought leadership and sharing expertise. For more information on how to position your company as a sponsor or exhibitor, contact Lauren Moras at 339-298-2172 or email lauren.moras@cbinet.com. Who Should Attend You will benefit from attending this event if you are a senior executive, senior director, director or manager from the pharmaceutical or biotech industries with responsibilities or involvement in the following areas: Regulatory Affairs • Regulatory Intelligence • Risk Management/REMS Pharmacovigilance/Drug Safety • Clinical Development • Epidemiology • Pharmacoepidemiology Formulary Development/CMC • Health/Government Policy • Medical Affairs This conference will also benefit consultants, CROs, central labs, drug safety service providers and companies providing services to the above audience. CBI’s Abuse Deterrent Formulations Summit focuses on critical abuse and misuse reduction strategies, including best practices for meeting regulatory requirements, implementing risk mitigation, developing protocols to evaluate liability and achieving an ADF label from the FDA. As the FDA continues to focus on reducing the abuse potential of opioids, it is more important than ever for bio/pharma manufacturers to ensure that new and existing products are meeting regulatory mandates and minimizing misuse potential and abuse liability. How will your organization respond? “While prescription opioids are an important component of pain management, abuse and misuse of these products have resulted in too many injuries and deaths across the United States. An important step towards the goal of creating safer opioids is the development of products that are specifically formulated to deter abuse.” - Douglas Throckmorton, M.D., Deputy Director, Regulatory Programs, Center for Drug Evaluation and Research, FDA *Source: FDA.gov, January, 2013 Conference Sponsors:
  • 3. DAY ONE Tuesday, May 19, 2015 7:45 Conference Registration and Breakfast 8:45 Chairperson’s Opening Remarks PennyLevin,Director,GlobalRegulatoryIntelligence&Policy,Teva Unravel Evolving ADF Regulatory Requirements to Minimize Human Abuse Liability 9:00 Policy Address Setting the Scene — The Future of Abuse Deterrent Formulations for Minimizing American Drug Abuse • Hear an overview of the prescription drug abuse epidemic, including the FDA’s Abuse Deterrent Opioids — Evaluation and Labeling final guidance * does the final guidance adequately assist sponsors with opioid drug product formulation development and set forth an understanding of what is expected? * how are the studies evaluated? What have been the subsequent labeling claims? * why generic draft guidance is so important? • Discuss how industry can reach the goal of decreasing abuse and misuse in the community • Evaluate ADFs as a method to reduce abuse while ensuring access to medication for patients with legitimate medical needs * discuss the extent to which abuse reduction can be measured * consider pros and cons of ADFs • Identify policy recommendations to transition the market to abuse-deterrent formulations for both branded and generic products * assess how policy recommendations impact market access StaceyL.Worthy,Esq.,AssociateAttorney,DCBA Law & Policy KyleSimon,Director,PolicyandAdvocacy,Center for Lawful Access and Abuse Deterrence (CLAAD) 10:00 State of the Union — What’s Going on in Congress and the States? Addressing prescription drug abuse is an issue high on legislative agendas in Washington, D.C. and in state legislatures across the country. Topics to be addressed in this session include: • What is going to happen in Congress? • Who are the key policymakers to watch? • What are they saying? • What states are leading the way to incentivize adoption of abuse deterrence formulations? • What is the industry doing to advance the cause? RobertJ.Falb,Director,GovernmentandPublicAffairsDepartment, Teva 10:30 Networking and Refreshment Break 11:00 Understand Pre-Marketing Regulatory Expectations and Clinical Processes to Ensure Compliance with FDA Final Guidance • Implement early planning and pre-IND considerations • Discuss ADF Category 1 Studies — Formulation analyses and in vitro testing • Examine ADF Category 2 (PK) and Category 3 (HAP) Studies — Design and FDA protocol review • Consider overall clinical program requirements — Collecting and reporting pertinent information • Prepare for the pre-NDA meeting and organize the NDA submission Discuss labeling considerations and the NDA review KevinHealy,Ph.D.,SeniorDirector,RegulatoryAffairs, Mallinckrodt Pharmaceuticals 11:45 Examine the Development of Opioid and Non-Opioid Abuse Deterrent Formulations to Reduce Liability and Meet Regulatory Expectations • Consider the deterrence science for rapid evolution of ADFs • Utilize formulation technologies and analytical, clinical and statistical evaluation methods to achieve FDA approval • Examine general considerations for study design • Explore the most common routes of abuse for the particular drug in development • Evaluate the concept of abuse potential • Implement approaches to assess the abuse potential of a drug product • Perform Human Abuse Potential (HAP) studies for drugs with addictive potential • Characterize the pharmacokinetic (PK)/ pharmacodynamic (PD) properties of a substance and a product • Discuss which opioid safety recommendations will be expanded into non-opioid drug development • Discover pitfalls and successes within the opioid market and how non-opioid products can learn from the failures and achievements TerriL.Morton,Ph.D.,SeniorPrincipalClinicalPharmacologist, Mallinckrodt Pharmaceuticals 12:30 Networking Luncheon REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
  • 4. 1:45 ROUNDTABLE Consider FDA Future Action for Generic Opioid Analgesic Treatment — Will Approval be Tied to ADF? During this interactive roundtable, attendees break into discussion groups to share insights on considerations for generic drug development with ADF. Participants then reconvene for shared learning to highlight key insights and discussion points of each individual group. Topics to be addressed include: • Examine FDA’s focus on ADF generic opioid development and what any changes in regulation could mean for development • Identify necessary considerations for generic product ADFs * will non-abuse deterrent opioid generics be kept off the market? * are there strategies for creating similar abuse deterrent formulations that may be able to match the branded product? * does a generic clinical study, claim and tier need to match that exactly of the branded product? * do the same suggestions that are laid out in the final guidance apply to generic products? • Gauge the potential for the future of generic drug development KevinSills,VicePresident,R&D,Atlantic Pharmaceuticals 2:45 Networking and Refreshment Break Develop Best Practices to Achieve FDA Approval and Ensure Market Success 3:15 Regulatory Liaison Best Practices for Managing Post-Submission Questions and Answers to and from the FDA • Create a rapid response team, including point persons for dossier review prior to submission * go through dossier with fine tooth comb to identify any potential questions from the FDA and multiple answers ahead of time • Ensure that appropriate R&D, regulatory, commercial, etc., team members are accessible when needed throughout the lifecycle of the submission; filing, acceptance, review • Respond to FDA questions, rapidly, with transparent and direct answers to facilitate a much cleaner review PennyLevin,Director,GlobalRegulatoryIntelligence&Policy,Teva 4:00 The Holy Grail of Abuse Deterrence • Examine the full extent of abuse deterrence — Can the current focus of ADF technologies on external manipulation of oral doses also protect the motivated abuser from accidental or intentional overdose? • Discuss the financial implications of developing abuse deterrence technologies RonGuido,CEO,ExxPharma Therapeutics, LLC 4:45 Close of Day One Networking, Wine and Cheese Reception immediately following the final session on day one DAY TWO Wednesday, May 20, 2015 8:00 Continental Breakfast 8:30 Chairperson’s Review of Day One PennyLevin,Director,GlobalRegulatoryIntelligence&Policy,Teva 8:45 INTERACTIVE LIVE POLLING Educate Medical Professionals, Patients and the Public on the Safe Use of Opioids and Stimulants How it works…Make sure to have your mobile device handy. Text answers to questions and see your results in real time. • Address how public policy collaborations with the government and with regulators need to evolve to provide the necessary formulated deterrence • Identify and define abuse deterrent developers’ role in educating the public for safe conduct and use of opioid and stimulant • Establish goals and aims of AD Coalition public policy initiatives DanCohen,Leader,U.S. Abuse Deterrent Coalition;Headof NorthAmericanGovernmentRelations,Grünenthal USA, Inc. Develop Strategies for Label Claims and Formulations in New and Existing Drugs 9:30 Generate and Translate Data from ADF Development into Label Claims and Communicate the Data to Various Stakeholders • Review the FDA final guidance on Abuse Deterrent Opioid Development to understand the following: * different categories of abuse deterrent studies * different tiers of claims for product labels * how the different categories of data do/do not translate to label claims REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
  • 5. • Appreciate the current approach and challenges in abuse deterrent opioid development in the context of “incremental improvement” • Identify appropriate ways for sponsors to communicate abuse deterrent claims in product labels • Anticipate challenges in the post-approval phase of an abuse deterrent opioid: * Category 4 abuse deterrent studies — A post-approval requirement * other ‘real world’ exposure of a product and its potential impact on its abuse deterrent profile JeffreyM.Dayno,M.D.,ChiefMedicalOfficer,Egalet Corporation 10:15 Networking and Refreshment Break 10:45 Leverage Pharmacokinetic Studies to Support Tier 2 Labeling Claims for Abuse Deterrent Opioids • Provide an overview of the FDA’s Abuse- Deterrent Opioids Guidance with respect to pharmacokinetic studies and Tier 2 labeling • Discuss the type of pharmacokinetic studies required to support Tier 2 claims • Consider different formulation manipulations and administration routes and how they can support Tier 2 labeling • Present strategies of using pharmacokinetic studies to help support Tier 1 and Tier 3 labeling claims JohnOldenhof,MSc,Ph.D.,SeniorDirectorScientificAffairs, INC Research 11:30 Utilize Formulation Technologies to Impart Abuse Deterrent Properties and ADF Testing • Discuss formulation technologies used in: * Aversion Oxycodone (formerly Oxecta) * Remoxy * Embeda * Bunavail • Examine the different types of ADF testing and the need for standards • Consider the potential for AD labeling • Deliberate what the future may hold for AD properties and testing JulieS.Ross,Ph.D.,Director,FormulationDevelopment, BioDelivery Sciences International 12:15 Networking Luncheon 1:30 The Search for New Pain Therapeutics with Low Inherent Abuse Potential — A Case for Prodrugs • Examine the history of prodrugs with abuse deterrent properties • Adapt biochemistry within clinical development to control abuser preference and enjoyment * prodrug development and combination of formulations • Consider options for manipulating drug products and extended-release formulations to decrease the ability for oral formulation to counteract overmedicating • Examine potential for use within the opioid analgesic drug class and the potential to evolve similar formulations for other addictive therapeutics SvenGuenther,Ph.D.,EVP,ResearchandDevelopment, KemPharm, Inc. 2:15 ROUNDTABLE True Objectives of Abuse Deterrence — Addiction vs. Abuse? While 15% of opioid abuse is through insufflation (snorting), or injection, the majority of abuse is that of quantity of opioid ingested. While the focus has been on decreasing the street value of opioids, the larger issue remains taking more opioid than prescribed. During this interactive roundtable, attendees break into discussion groups to share insights on objectives for minimizing abuse. Participants then reconvene for shared learning to highlight key insights and discussion points of each individual group. Questions to be addressed include: • Should we be focusing on how to make effective pain medications that are less addictive, with lower amounts of euphoria or withdrawal symptoms? • What can we learn from studying patient preference and the effect of different opioids on different patients types? • Can we avoid situations where acute patients become chronic patients with managing medication therapy management? • Physical manipulation of opioids only addresses part of the problem; are likability and abuse potential truly the same thing? TimHermes,VicePresident,GovernmentAffairsandAlliance Development,Collegium Pharmaceuticals, Inc. 3:00 Close of Conference REGISTER AT WWW.CBINET.COM/ADF • 800-817-8601
  • 6. SCAN HERE CBI 70 Blanchard Road Burlington, MA 01803 4WAYS TO REGISTER NOW! PHONE 800-817-8601 339-298-2100 outside the U.S. E-MAIL cbireg@cbinet.com WEBSITE www.cbinet.com/adf LIVE CHAT www.cbinet.com/adf Life Sciences Abuse Deterrent Formulations Summit PC15098 VENUE: DoubleTree by Hilton Silver Spring 8727 Colesville Road Silver Spring, Maryland 20910 Phone Reservations: (800) 222-8733 Hotel Direct Line: (301) 589-5200 ACCOMMODATIONS: To receive CBI’s special discounted hotel rate online or by phone, please go to: • Online: www.cbinet.com/adf • Phone reservations: (800) 222-8733 and mention CBI’s Abuse Deterrent Formulations. Book Now! The DoubleTree by Hilton Silver Spring is accepting reservations on a space and rate availability basis. Rooms are limited, so please book early. All travel arrangements subject to availability. PLEASE NOTE: All hotel reservations for this conference should be booked directly with the hotel. CBI does not use Housing Bureaus and none are authorized to call on our behalf. REGISTRATION FEE: ADVANTAGE PRICING Standard Conference $1899 $2199 Register by March 27, 2015 and SAVE $300. Fee includes continental breakfast, lunch, wine and cheese reception, refreshments and conference documentation. Please make checks (in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.) PLEASE NOTE: All advertised discounts are taken from the full, Standard Rate. TEAM DISCOUNT: For every three paying registrations from your company, you will receive a fourth complimentary* registration to the conference (must register four at same time to qualify). To receive the team discount you must register with our customer service department by calling 339-298-2100. * Advantage pricing rates do apply when applicable. Offer may not be combined with any other special pricing promotions. Offer may be used at CBI co-located events. SATISFACTION GUARANTEED: CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference, a credit will be awarded towards a comparable CBI conference of your choice. Please contact 800-817- 8601 for further information. Advanced preparation for CBI conferences is not required. SUBSTITUTION AND CANCELLATION: Your registration may be transferred to a member of your organization up to 24 hours in advance of the conference. Cancellations received in writing on or before 14 days prior to the start date of the event will be refunded, less a $399 administrative charge. No refunds will be made after this date; however, the registration fee less the $399 administrative charge can be credited to another CBI conference if you register within 30 days from the date of this conference to an alternative CBI conference scheduled within the next six months. In case of conference cancellation, CBI’s liability is limited to refund of the conference registration fee only. CBI reserves the right to alter this program without prior notice. Please Note: Speakers and agenda are subject to change. In the event of a speaker cancellation, every effort to find a suitable replacement will be made without notice. The opinions of the conference faculty do not necessarily reflect those of the companies they represent or CBI. REGISTE R AT WWW.CBINET.COM/ADF • 800-817-8601 R E G I S T E R BY M A R C H 2 7, 2 0 1 5 A N D S AV E $ 3 0 0 ! MAY 19-20, 2015 • DOUBLETREE BY HILTON • SILVER SPRING, MD Navigate the Rapidly Changing Requirements for Minimizing the Misuse Potential of Highly Abused Drugs ANY QUESTIONS OR TO REGISTER CALL Christian Alongi 339-298-2131 or FAX TO MY ATTENTION 781-939-2694 email: christian.alongi@cbinet.com